Literature DB >> 18258175

A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization.

Judith Müller1, Jochen Schust, Thorsten Berg.   

Abstract

Signal transducer and activator of transcription 5b (STAT5b) is constitutively activated in many human tumors. Activity of STAT5b requires binding of its Src homology 2 (SH2) domain to certain phosphotyrosine-containing sequences. We have developed a high-throughput assay based on fluorescence polarization that allows screening of chemical libraries for compounds that inhibit STAT5b by interfering with the function of its SH2 domain. The assay, which is based on binding between a fluorescein-labeled phosphotyrosine peptide derived from the erythropoietin receptor to the STAT5b SH2 domain, is stable with regard to dimethyl sulfoxide concentration and time and has a Z' value of 0.66+/-0.11 in a 384-well format.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258175     DOI: 10.1016/j.ab.2008.01.017

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  15 in total

1.  Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.

Authors:  Jason Lamontagne; Courtney Mills; Richeng Mao; Cally Goddard; Dawei Cai; Haitao Guo; Andy Cuconati; Timothy Block; Xuanyong Lu
Journal:  Antiviral Res       Date:  2013-02-13       Impact factor: 5.970

2.  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.

Authors:  Vijay M Shahani; Peibin Yue; Steven Fletcher; Sumaiya Sharmeen; Mahadeo A Sukhai; Diana P Luu; Xiaolei Zhang; Hong Sun; Wei Zhao; Aaron D Schimmer; James Turkson; Patrick T Gunning
Journal:  Bioorg Med Chem       Date:  2010-12-09       Impact factor: 3.641

Review 3.  The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain.

Authors:  John S McMurray; Pijus K Mandal; Warren S Liao; Jim Klostergaard; Fredika M Robertson
Journal:  JAKSTAT       Date:  2012-10-01

4.  Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a.

Authors:  Nagarajan Elumalai; Angela Berg; Kalaiselvi Natarajan; Andrej Scharow; Thorsten Berg
Journal:  Angew Chem Int Ed Engl       Date:  2015-02-20       Impact factor: 15.336

Review 5.  Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.

Authors:  Angelika Berger; Veronika Sexl; Peter Valent; Richard Moriggl
Journal:  Oncotarget       Date:  2014-10-30

6.  Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.

Authors:  Abbarna A Cumaraswamy; Andrew M Lewis; Mulu Geletu; Aleksandra Todic; Diego B Diaz; Xin Ran Cheng; Carla E Brown; Rob C Laister; David Muench; Kagan Kerman; H Leighton Grimes; Mark D Minden; Patrick T Gunning
Journal:  ACS Med Chem Lett       Date:  2014-09-19       Impact factor: 4.345

7.  Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.

Authors:  Kazuyuki Takakuma; Naohisa Ogo; Yutaka Uehara; Susumu Takahashi; Nao Miyoshi; Akira Asai
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.

Authors:  Sophia Pinz; Samy Unser; Susanne Brueggemann; Elisabeth Besl; Nafisah Al-Rifai; Hermina Petkes; Sabine Amslinger; Anne Rascle
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

Review 9.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

10.  The natural chemopreventive agent sulforaphane inhibits STAT5 activity.

Authors:  Sophia Pinz; Samy Unser; Anne Rascle
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.